Skip to main content

Treatment Refractory MAC Lung Disease clinical trials at UCSF

1 in progress, 0 open to eligible people

Showing trials for
  • Epetraborole in Patients With Treatment-refractory MAC Lung Disease

    Sorry, in progress, not accepting new patients

    This is a pivotal Phase 2/3, double-blind, placebo-controlled study of epetraborole + OBR (Optimized Background Regimen) versus placebo + OBR in patients with treatment-refractory MAC lung disease. This study will enroll adult patients with treatment-refractory MAC lung disease who meet all eligibility criteria (including clinical, radiographic, and microbiological criteria).

    San Francisco, California and other locations

Last updated: